Akalux (cetuximab sarotalocan)

News alerts, weekly reports and conference planners

Company:

Rakuten Medical

Drug class:

EGFR-targeted-dye conjugate

‹

›

Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.

No biomarker	Head and Neck Cancer	No biomarker	Head and Neck Cancer	cetuximab sarotalocan Sensitive: A1 - Approval cetuximab sarotalocan Sensitive : A1	cetuximab sarotalocan Sensitive: A1 - Approval cetuximab sarotalocan Sensitive : A1
PD-L1 underexpression	Squamous Cell Carcinoma of Head and Neck	PD-L1 underexpression	Squamous Cell Carcinoma of Head and Neck	cetuximab sarotalocan Sensitive: C3 – Early Trials cetuximab sarotalocan Sensitive : C3	cetuximab sarotalocan Sensitive: C3 – Early Trials cetuximab sarotalocan Sensitive : C3

Associations
(2)